Login to Your Account

House Of Lords Rules In TKT's Favor On EPO Patent Claims

By Nuala Moran

Wednesday, October 27, 2004
LONDON - Amgen Inc. received a double blow against the patent covering its blockbuster drug erythropoietin (EPO) when the UK House of Lords reversed an earlier legal decision and ruled the claims of the patent are too broad, while at the same time upholding an earlier judgment that Transkaryotic Therapies Inc.'s method of producing EPO does not infringe Amgen's EPO patent. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription